Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics' stock has experienced a significant increase of 70.18% between January 13, 2025, and January 9, 2026, hitting a new 52-week high of $4.18 on January 8, 2026. Recent earnings reports have shown mixed results but overall growth. The company completed a $75 million capital raise in 2025 and reached patent settlement agreements restricting generic entry until April 2040. Regulatory approvals in Japan and Canada for its products have also been positive developments. However, there have been instances of insider selling.

Esperion Therapeutics' product demand experiences some seasonality, particularly in the U.S. lipid-lowering market. The first quarter typically faces seasonal headwinds due to changes in Medicare Part D and higher out-of-pocket costs for patients. However, early trends in Q2 2025 indicated an encouraging return to stronger growth.

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral therapies for patients with elevated LDL-C. Its core business revolves around addressing cardiovascular disease by targeting LDL cholesterol. The company's major marketed products include NEXLETOL and NEXLIZET tablets, which are oral, once-daily, non-statin medicines used for the treatment of primary hyperlipidemia. Esperion also produces NILEMDO and NUSTENDI, which also aim to lower LDL-C and cardiovascular risk. The company is also investing in its Next Gen Program to explore new therapeutic opportunities.

Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan, United States. The company has a growing global presence through strategic partnerships, with products approved in the U.S. and Europe. Daiichi Sankyo Europe is a key partner across 30 countries in the European Union. Esperion also has license and collaboration agreements with Otsuka Pharmaceutical Co., Ltd. for Japan, where regulatory approval and favorable National Health Insurance price listing were received in late 2025. Regulatory approval for NILEMDO was received in Canada in late 2025 through its partner HLS Therapeutics, with NEXLIZET approval expected in 2026. Neopharm Israel is expected to receive regulatory approval for NEXLETOL and NEXLIZET in the first half of 2026, and CSL Seqirus, Esperion's partner in Australia and New Zealand, filed a marketing application in July 2025, anticipating market approval in Q4 2026.

Esperion Therapeutics has maintained a generally positive brand reputation, particularly within the medical and investment communities. The company's bempedoic acid products have received growing global guideline endorsements. Analysts generally hold a "Moderate Buy" consensus rating for Esperion, with an average price target suggesting significant upside potential. The company emphasizes its commitment to quality and a patient-centric approach. However, the company has faced financial challenges, including missing EPS forecasts and concerns about mounting losses and increased operating costs.

Esperion Therapeutics, Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the shares. As of recent filings, 299 institutional owners hold a total of 118,741,853 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Two Seas Capital LP, Wasatch Advisors Inc, PenderFund Capital Management Ltd., Geode Capital Management, Llc, and State Street Corp. Insider ownership stands at approximately 1.49% to 17.28% of the company's stock, with Target N.V. Biotech being a significant individual shareholder.